Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Interest Income

Income earned on cash, deposits, and investments held by the company.

Definium Therapeutics, Inc.NASDAQ: DFTX

Interest Income · Q3 FY2026 · quarter ended Sep 2026

Interest income growth accelerates

Q3 FY2026 interest income of $10.14M rose 348.2% year over year, ahead of the +92.4% change in trailing-twelve-month interest income. Sequentially, it rose 182.7% from the prior quarter. Over 3 fiscal years it compounded at +94.3% a year.

Context

  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +348.2% holds above the trailing-twelve-month pace of +92.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$10.14M+182.7% QoQ
Last fiscal yearDec 2025
$10.96M-5.2% YoY
LTMSep 2026
$20.67M+92.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+348.2%——
1 year-5.2%——
3-year CAGR+94.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
10.96M USD
Year-over-year change
-5.2%

Interest Income vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +92.4% is the 3rd highest of 9, against a peer median of +37.0%.
  • Over three fiscal years its annual growth of +94.3% compares with a peer median of +134.3%.
DFTX Competitors
Interest Income for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$25.98M USD+425.9%——
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$20.67M USD+92.4%+94.3%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$14.93M USD+11.7%—74.6%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$7.18M USD+62.2%+134.3%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$6.36M USD—+277.3%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$6.34M USD-30.5%+286.9%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$6.07M USD-63.6%+22.3%—
GHRSGH Research PLCLTM Mar 2026$2.32M USD-61.0%+45.2%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$2.04M USD——0.3%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$1.85M USD+118.3%+19.4%—
ATHEAlterity Therapeutics LimitedFY2025A$446.29K AUD+66.3%+462.8%8.2%
Peer median (excluding DFTX) —+37.0%+134.3%8.2%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue003.16M527K0
Gross Profit00(3.16M)(527K)0
Gross Margin—————
Research & Development34.79M36.17M48.96M65.3M117.67M
Selling, General & Admin59.07M30.16M41.74M38.62M48.64M
Operating Expenses93.85M66.33M90.7M103.39M166.31M
Depreciation & Amortization2.62M3.18M3.16M527K0
EBITDA(91.22M)(52.12M)(92.57M)(105.87M)(178.31M)
EBITDA Margin—————
Operating Income(93.85M)(66.33M)(93.87M)(103.92M)(166.31M)
Operating Margin—————
Interest Income01.5M5.58M11.56M10.96M
Interest Expense359K1.5M920K2.28M5.48M
Other Income / Expenses(339K)9.54M(1.87M)(4.76M)(17.48M)
Income Before Tax(94.19M)(56.8M)(95.73M)(108.68M)(183.79M)
Pre-Tax Margin—————
Income Tax Expense(1.16M)0000
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Net Margin—————
EPS (Basic)(3.40)(1.53)(2.44)(1.54)(2.06)
EPS (Diluted)(3.40)(1.53)(2.44)(0.15)(2.06)
Weighted Avg Shares27.38M30.86M39.16M70.46M89.33M
Weighted Avg Shares (Diluted)27.38M30.86M39.16M704.61M89.33M

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.